• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Altimmune Inc (NQ: ALT )

    7.230 +0.030 (+0.42%)
    Streaming Delayed Price Updated: 9:50 AM EDT, Apr 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 184,342
    Open 7.180
    Bid (Size) 7.230 (6)
    Ask (Size) 7.250 (3)
    Prev. Close 7.200
    Today's Range 6.900 - 7.240
    52wk Range 2.090 - 14.84
    Shares Outstanding 70,895,286
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
    These weight loss drug stocks are relatively unknown and brimming with potential following the massive success of Novo Nordisk and Eli Lilly. 
    Via InvestorPlace
    Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
    The GLP-1 weight loss trend continues to flourish, and the ante keeps rising; see how the winner between Wegovy and Zepbound can help your portfolio 
    Via MarketBeat

    Performance

    YTD
    -31.27%
    -31.27%
    1 Month
    -16.42%
    -16.42%
    3 Month
    -22.09%
    -22.09%
    6 Month
    +211.64%
    +211.64%
    1 Year
    +38.51%
    +38.51%

    More News

    Read More
    Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential
    Via The Motley Fool
    3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024
    Via InvestorPlace
    Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.
    Via The Motley Fool
    How Is The Market Feeling About Altimmune?
    Via Benzinga
    If You Invested $100 In This Stock 5 Years Ago, You Would Have $300 Today
    Via Benzinga
    ALT Stock Earnings: Altimmune Beats EPS for Q4 2023
    Via InvestorPlace
    Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?
    Via MarketBeat
    Exposures Product Safety
    Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Altimmune's Earnings Outlook
    Via Benzinga
    (ALT) - Analyzing Altimmune's Short Interest
    Via Benzinga
    Here's How Much $100 Invested In Altimmune 5 Years Ago Would Be Worth Today
    Via Benzinga
    REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday
    Via Benzinga
    Stock Market Rally Shows Breadth As Leaders Take A Breath: Weekly Review
    Via Investor's Business Daily
    7 Stocks That Will Drive the Weight Loss Drugs Market
    Via MarketBeat
    Why Is Obesity Drug Developer Altimmune Stock Trading Lower On Wednesday?
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Earnings Scheduled For March 27, 2024
    Via Benzinga
    Cramer Calls Datadog 'Dynamite,' Puts SoFi In Dog House: 'What The Heck Is Going On'
    Via Benzinga
    Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?
    Via The Motley Fool
    ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
    Via NewMediaWire
    ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
    Via TheNewswire.com
    ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
    Via NewMediaWire
    ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
    Via TheNewswire.com
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.